Abstract
Background: Anaphylaxis, which is rare, has been reported after COVID-19 vaccination, but its management is not standardized. Method: Members of the European Network for Drug Allergy and the European Academy of Allergy and Clinical Immunology interested in drug allergy participated in an online questionnaire on pre-vaccination screening and management of allergic reactions to COVID-19 vaccines, and literature was analysed. Results: No death due to anaphylaxis to COVID-19 vaccines has been confirmed in scientific literature. Potential allergens, polyethylene glycol (PEG), polysorbate and tromethamine are excipients. The authors propose allergy evaluation of persons with the following histories: 1—anaphylaxis to injectable drug or vaccine containing PEG or derivatives; 2—anaphylaxis to oral/topical PEG containing products; 3—recurrent anaphylaxis of unknown cause; 4—suspected or confirmed allergy to any mRNA vaccine; and 5—confirmed allergy to PEG or derivatives. We recommend a prick-to-prick skin test with the left-over solution in the suspected vaccine vial to avoid waste. Prick test panel should include PEG 4000 or 3500, PEG 2000 and polysorbate 80. The value of in vitro test is arguable. Conclusions: These recommendations will lead to a better knowledge of the management and mechanisms involved in anaphylaxis to COVID-19 vaccines and enable more people with history of allergy to be vaccinated.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Allergy: European Journal of Allergy and Clinical Immunology |
| Vol/bind | 77 |
| Udgave nummer | 8 |
| Sider (fra-til) | 2292-2312 |
| ISSN | 0105-4538 |
| DOI | |
| Status | Udgivet - 2022 |
Bibliografisk note
Publisher Copyright:© 2022 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Allergies and COVID-19 vaccines : An ENDA/EAACI Position paper. / Barbaud, Annick; Garvey, Lene Heise; Arcolaci, Alessandra; Brockow, Knut; Mori, Francesca; Mayorga, Cristobalina; Bonadonna, Patrizia; Atanaskovic-Markovic, Marina; Moral, Luis; Zanoni, Giovanna; Pagani, Mauro; Soria, Angèle; Jošt, Maja; Caubet, Jean-Christoph; Carmo, Abreu; Mona, Al Ahmad; Alvarez-Perea, Alberto; Bavbek, Sevim; Benedetta, Biagioni; Bilo, M Beatrice; Blanca-López, Natalia; Bogas, Herrera Gádor; Buonomo, Alessandro; Calogiuri, Gianfranco; Carli, Giulia; Cernadas, Josefina; Cortellini, Gabriele; Celik, Gülfem; Demir, Semra; Doña, Inmaculada; Dursun, Adile Berna; Eberlein, Bernadette; Faria, Emilia; Fernandes, Bryan; Garcez, Tomaz; Garcia-Nunez, Ignacio; Gawlik, Radoslaw; Gelincik, Asli; Gomes, Eva; Gooi, Jimmy H. C.; Grosber, Martine; Gülen, Theo; Hacard, Florence; Hoarau, Cyrille; Janson, Christer; Johnston, Sebastian L; Joerg, Lukas; Kepil Özdemir, Seçil; Klimek, Ludger; Košnik, Mitja; Kowalski, Marek L; Kuyucu, Semanur; Kvedariene, Violeta; Laguna, Jose Julio; Lombardo, Carla; Marinho, Susana; Merk, Hans; Meucci, Elisa; Morisset, Martine; Munoz-Cano, Rosa; Murzilli, Francesco; Nakonechna, Alla; Popescu, Florin Dan; Porebski, Grzegorz; Radice, Anna; Regateiro, Frederico S.; Röckmann, Heike; Romano, Antonino; Sargur, Ravishankar; Sastre, Joaquin; Hofmeier, Kathrin Scherer; Sedláčková, Lenka; Sobotkova, Marta; Terreehorst, Ingrid; Treudler, Regina; Walusiak-Skorupa, Jolanta; Wedi, Bettina; Wöhrl, Stefan; Zidarn, Mihael; Zuberbier, Torsten; Agache, Ioana; Torres, Maria J.
I: Allergy: European Journal of Allergy and Clinical Immunology, Bind 77, Nr. 8, 2022, s. 2292-2312.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Allergies and COVID-19 vaccines
T2 - An ENDA/EAACI Position paper
AU - Barbaud, Annick
AU - Garvey, Lene Heise
AU - Arcolaci, Alessandra
AU - Brockow, Knut
AU - Mori, Francesca
AU - Mayorga, Cristobalina
AU - Bonadonna, Patrizia
AU - Atanaskovic-Markovic, Marina
AU - Moral, Luis
AU - Zanoni, Giovanna
AU - Pagani, Mauro
AU - Soria, Angèle
AU - Jošt, Maja
AU - Caubet, Jean-Christoph
AU - Carmo, Abreu
AU - Mona, Al Ahmad
AU - Alvarez-Perea, Alberto
AU - Bavbek, Sevim
AU - Benedetta, Biagioni
AU - Bilo, M Beatrice
AU - Blanca-López, Natalia
AU - Bogas, Herrera Gádor
AU - Buonomo, Alessandro
AU - Calogiuri, Gianfranco
AU - Carli, Giulia
AU - Cernadas, Josefina
AU - Cortellini, Gabriele
AU - Celik, Gülfem
AU - Demir, Semra
AU - Doña, Inmaculada
AU - Dursun, Adile Berna
AU - Eberlein, Bernadette
AU - Faria, Emilia
AU - Fernandes, Bryan
AU - Garcez, Tomaz
AU - Garcia-Nunez, Ignacio
AU - Gawlik, Radoslaw
AU - Gelincik, Asli
AU - Gomes, Eva
AU - Gooi, Jimmy H. C.
AU - Grosber, Martine
AU - Gülen, Theo
AU - Hacard, Florence
AU - Hoarau, Cyrille
AU - Janson, Christer
AU - Johnston, Sebastian L
AU - Joerg, Lukas
AU - Kepil Özdemir, Seçil
AU - Klimek, Ludger
AU - Košnik, Mitja
AU - Kowalski, Marek L
AU - Kuyucu, Semanur
AU - Kvedariene, Violeta
AU - Laguna, Jose Julio
AU - Lombardo, Carla
AU - Marinho, Susana
AU - Merk, Hans
AU - Meucci, Elisa
AU - Morisset, Martine
AU - Munoz-Cano, Rosa
AU - Murzilli, Francesco
AU - Nakonechna, Alla
AU - Popescu, Florin Dan
AU - Porebski, Grzegorz
AU - Radice, Anna
AU - Regateiro, Frederico S.
AU - Röckmann, Heike
AU - Romano, Antonino
AU - Sargur, Ravishankar
AU - Sastre, Joaquin
AU - Hofmeier, Kathrin Scherer
AU - Sedláčková, Lenka
AU - Sobotkova, Marta
AU - Terreehorst, Ingrid
AU - Treudler, Regina
AU - Walusiak-Skorupa, Jolanta
AU - Wedi, Bettina
AU - Wöhrl, Stefan
AU - Zidarn, Mihael
AU - Zuberbier, Torsten
AU - Agache, Ioana
AU - Torres, Maria J.
N1 - Publisher Copyright: © 2022 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
PY - 2022
Y1 - 2022
N2 - Background: Anaphylaxis, which is rare, has been reported after COVID-19 vaccination, but its management is not standardized. Method: Members of the European Network for Drug Allergy and the European Academy of Allergy and Clinical Immunology interested in drug allergy participated in an online questionnaire on pre-vaccination screening and management of allergic reactions to COVID-19 vaccines, and literature was analysed. Results: No death due to anaphylaxis to COVID-19 vaccines has been confirmed in scientific literature. Potential allergens, polyethylene glycol (PEG), polysorbate and tromethamine are excipients. The authors propose allergy evaluation of persons with the following histories: 1—anaphylaxis to injectable drug or vaccine containing PEG or derivatives; 2—anaphylaxis to oral/topical PEG containing products; 3—recurrent anaphylaxis of unknown cause; 4—suspected or confirmed allergy to any mRNA vaccine; and 5—confirmed allergy to PEG or derivatives. We recommend a prick-to-prick skin test with the left-over solution in the suspected vaccine vial to avoid waste. Prick test panel should include PEG 4000 or 3500, PEG 2000 and polysorbate 80. The value of in vitro test is arguable. Conclusions: These recommendations will lead to a better knowledge of the management and mechanisms involved in anaphylaxis to COVID-19 vaccines and enable more people with history of allergy to be vaccinated.
AB - Background: Anaphylaxis, which is rare, has been reported after COVID-19 vaccination, but its management is not standardized. Method: Members of the European Network for Drug Allergy and the European Academy of Allergy and Clinical Immunology interested in drug allergy participated in an online questionnaire on pre-vaccination screening and management of allergic reactions to COVID-19 vaccines, and literature was analysed. Results: No death due to anaphylaxis to COVID-19 vaccines has been confirmed in scientific literature. Potential allergens, polyethylene glycol (PEG), polysorbate and tromethamine are excipients. The authors propose allergy evaluation of persons with the following histories: 1—anaphylaxis to injectable drug or vaccine containing PEG or derivatives; 2—anaphylaxis to oral/topical PEG containing products; 3—recurrent anaphylaxis of unknown cause; 4—suspected or confirmed allergy to any mRNA vaccine; and 5—confirmed allergy to PEG or derivatives. We recommend a prick-to-prick skin test with the left-over solution in the suspected vaccine vial to avoid waste. Prick test panel should include PEG 4000 or 3500, PEG 2000 and polysorbate 80. The value of in vitro test is arguable. Conclusions: These recommendations will lead to a better knowledge of the management and mechanisms involved in anaphylaxis to COVID-19 vaccines and enable more people with history of allergy to be vaccinated.
KW - allergy test
KW - anaphylaxis
KW - COVID-19 vaccine
KW - mRNA vaccines
KW - risk assessment
U2 - 10.1111/all.15241
DO - 10.1111/all.15241
M3 - Journal article
C2 - 35112371
AN - SCOPUS:85126057228
VL - 77
SP - 2292
EP - 2312
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
SN - 0105-4538
IS - 8
ER -